ACTIV-6

COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

About the Study

Currently Recruiting: Participants

Study Drug/Intervention: Metformin

Study Timeline: This study is expected to conclude in June 2024.

Visit the Study Website

ClinicalTrials.gov ID: NCT04885530

 

Objective

The purpose of ACTIV-6 is to evaluate the effectiveness of repurposed medications in nonhospitalized participants with mild to moderate COVID-19.

Inclusion & Exclusion Criteria

Participation Criteria

1. Completed Informed Consent

2. Age ≥ 30 years old

3. Confirmed SARS-CoV-2 infection (or reinfection) by any authorized or approved PCR or antigen test collected within 10 days of screening

4. Two or more current symptoms of acute infection for ≤ 7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell.

Sponsor/Funding

National Center for Advancing Translational Sciences (NCATS)

Learn More